Shrinking Lung Syndrome as a Manifestation of Pleuritis: Are Surface Forces and Surfactant the Pathophysiological Link?

To the Editor:

I read with great interest the paper by Henderson, et al1 on shrinking lung syndrome (SLS) as a manifestation of pleuritis. A decrease in lung compliance in patients with SLS was found. Analysis of the computed tomography images did not show any evidence of parenchymal lung disease. Further, the study subjects with SLS had intact corrected DLCO values. The authors appropriately point out that both of these important observations make interstitial lung disease an unlikely cause of the decreased lung compliance. The authors described that a comparable decrease in lung compliance has been observed in patients who are chronically restricted to lower lung volumes; for example, patients with spinal cord injury or muscular dystrophy. The authors further describe that tissue remodeling with changes in the elasticity of the lung tissue are the proposed underlying pathophysiology. It is important to point out that none of the studies cited as reference for tissue remodeling in the setting of chronically restricted lung volumes show direct evidence of tissue remodeling in the lung.

Conversely, chest wall strapping is an experimental procedure that is used to model the effect of breathing at low lung volumes on pulmonary physiology2,3,4. Restrictions to inspiration by chest wall strapping of normal volunteers lead to an immediate decrease in lung compliance2,3,4. This is fully reversible by relieving the chest wall strapping and allowing again for deep inspirations to total lung capacity. Restriction to 60% to 65% of the normal total lung capacity by chest wall strapping was sufficient to demonstrate the decrease in lung compliance3. These immediate and immediately reversible changes in lung compliance with chest wall strapping strongly suggest that changes in surface forces at the air liquid interface of the lung are the underlying etiology for the lung compliance changes3. Surfactant is the main regulator of surface forces in the lung5. In that context, alterations in surfactant have also been implicated in the pathophysiology of SLS6.

Breathing at lower lung volumes secondary to pleuritis, as described in the study by Henderson, et al1, is conceptually similar to chest wall strapping. It is very likely that changes in surface forces and possibly surfactant play a role in the observed decreased lung compliance in patients with pleuritis.

MICHAEL EBERLEIN, MD, PhD, Division of Pulmonary, Critical Care and Occupational Medicine, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, C 33 GH, Iowa City, Iowa 52242, USA. Address correspondence to Dr. Eberlein. E-mail: michael-eberlein@uiowa.edu

REFERENCES


J Rheumatol 2013;40:11; doi:10.3899/jrheum.130764
Dr. Henderson, et al reply

To the Editor:

We are grateful for the thoughtful commentary of Dr. Eberlein on our recent study of shrinking lung syndrome (SLS). We reported that SLS was associated with 2 abnormalities of pulmonary physiology: (1) reduced inspiratory force at high but not low lung volumes, a pattern noted in pleuritis; and (2) markedly reduced lung compliance, in the absence of interstitial lung disease as determined by chest tomography and gas diffusion. Recognizing that SLS is frequently associated with episodes of chest pain and/or small pleural effusions, and presents clinically as gradually progressive dyspnea that stops short of respiratory failure, we proposed a new working model for SLS. Briefly, we hypothesized that SLS begins with pleuritis that triggers voluntary and reflex splinting of the chest wall. Chronic hypoinflation leads to gradual but persistent impairment of compliance, a process recognized in patients with high spinal cord injuries and in other conditions associated with chronically low lung volumes and thought to be mediated by remodeling of the pulmonary parenchyma. Reduced lung compliance in turn favors worsening hypoinflation, setting up a cycle of gradually progressive pulmonary restriction that stabilizes once further hypoinflation is prohibited by the patient’s respiratory drive.

Dr. Henderson points out that remodeling is not the only pathway to hypoinflation-induced impairment of lung compliance. As he notes, studies in healthy volunteers show that chest strapping or voluntary low-volume breathing also produces a rapid loss of lung compliance, one that is not completely understood but typically attributed to an increase in alveolar surface tension. Could this effect be the mechanism of compliance loss in SLS, without invoking structural changes in the lung, for which, as Dr. Henderson notes, there is little understanding at the histopathological level in either SLS or other chronically volume-restricted states?

We agree that this is a key question and recognize that multiple factors could contribute to loss of compliance in individuals with SLS, potentially coming into play at different phases of the disease. Indeed, improvement with treatment in many patients points to a reversible component in SLS-associated lung dysfunction. However, we suggest that the physiology described is unlikely to be the major determinant of the SLS phenotype. As Dr. Henderson notes, impairment of compliance by chest strapping is quickly reversed — a few deep breaths are sufficient to restore normal compliance measures. This was not the case with our patients with SLS, in whom compliance remained low through the course of pulmonary testing that included maximal respiratory efforts. Further, in 1 patient studied months after symptomatic improvement, we found that lung compliance remained markedly low. These findings suggest that the physiology of SLS more closely resembles that of spinal cord injury, where chronic hypoventilation is associated with a fixed impairment of compliance that cannot be reversed even after mechanical ventilation to maximally inflate the lung. Careful investigation of these patients has suggested that their pulmonary physiology is best represented by a model of alveolar loss, with normal elastic/surface tension measurements of the residual alveoli. Therefore, we have proposed that the same kind of parenchymal changes ("remodeling") occur in SLS, potentially accounting for the progressive and potentially persistent character of the restrictive changes.

Dr. Eberlein raises the interesting possibility that an abnormality in surfactant, as a major determinant of alveolar surface tension, may contribute to SLS. This hypothesis was suggested in the original description of SLS, but to our knowledge no supporting data have since emerged, although the question has not yet been thoroughly studied. Surfactant represents a complex lipoprotein mixture. Neutones with surfactant deficiency present with widespread atelectasis, and atelectasis and recurrent infections are also noted in children and adults with mutations affecting surfactant genes. These phenotypes are not particularly reminiscent of SLS. Further, SLS is commonly preceded by clinical or radiological evidence for pleuritis, an association that would not be expected if the primary process were a surfactant abnormality. Thus, while surfactant may play some role in SLS physiology, we doubt that surfactant abnormalities represent a primary factor in disease pathogenesis.

These considerations notwithstanding, we are indebted to Dr. Eberlein for highlighting the possible role of rapid and reversible as well as slowly progressive and fixed causes of impaired lung compliance in SLS. His comments serve as a reminder that the model we have proposed is a working hypothesis whose validation will require further study, including longterm followup of additional patients and examination of affected lung tissue to define the histopathological basis of persistently impaired lung compliance.

LAUREN A. HENDERSON, MD, Division of Immunology, Boston Children’s Hospital, the Department of Anesthesia and Critical Care, Beth Israel Deaconess Medical Center; STEPHEN H. LORING, MD, Department of Anesthesia and Critical Care, Beth Israel Deaconess Medical Center; PAUL F. DELLARIPA, MD, Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital; and PETER A. NIGROVIC MD, Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, and Division of Immunology, Boston Children’s Hospital, Boston, Massachusetts, USA. Address correspondence to Dr. P.A. Nigrovic, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Smith Building Room 516b, One Jimmy Fund Way, Boston, MA 02115, USA.

E-mail: pignigrovic@partners.org

REFERENCES


J Rheumatol 2013;40:11; doi:10.3899/jrheum.130897